Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.
You may also be interested in...
Allergan and Molecular Partners said dosing of the VEGF inhibitor every eight or 12 weeks was non-inferior to Lucentis every four weeks. But while AMD patients would enjoy fewer sharp pokes in the eye, about 15% may experience inflammation – at least until a new formulation is available.
After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.
Attention Turns To Celgene's Other Pipeline Prospects Following Second Positive Luspatercept Read-Out
Celgene and Acceleron's novel erythroid maturation agent, luspatercept, has reported positive Phase III results in a second potential indication, beta-thalassemia, and approval filings are confirmed for the first half of 2019.